USPTO serial 79379326
ENDOPORE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 27, 2025
- Examiner
- HARMON, RAYMOND E
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ENDOPORE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jordan Arnot Leahey
Jordan Arnot Leahey CM Law PLLC13101 Preston Road, Ste. 110-1520Dallas, TX 75240United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for gene editing; veterinary preparations for gene editing; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; veterinary preparations for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical preparations for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for gene editing; pharmaceutical substances for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical substances for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical compositions and preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer | ACTIVE | — |
| 035 | Compilation of information into computer databases in the medical field | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research, technological research, and research and design, all in the fields of intracellular delivery of drugs, gene editing, intracellular delivery of therapeutic substances focused on the development of RNA therapies, intracellular delivery of therapeutic substances focused on non-viral delivery technology, intracellular delivery of nucleic acids, intracellular delivery of proteins, intracellular delivery of peptides, and intracellular delivery of small molecules; research services in the fields of intracellular delivery of drugs, gene editing, intracellular delivery of therapeutic substances focused on the development of RNA therapies, intracellular delivery of therapeutic substances focused on non-viral delivery technology, intracellular delivery of nucleic acids, intracellular delivery of proteins, intracellular delivery of peptides, and intracellular delivery of small molecules; clinical trials, namely, scientific research in the nature of conducting clinical trials for others; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; medical research laboratories; medical research laboratory services; medical research; medical research services; pharmaceutical drug development services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of vaccines and medicines; research of pharmaceuticals; research relating to medicines; research relating to pharmaceuticals; scientific investigations for medical purposes; scientific research and development; scientific research in the field of pharmacy; medical research, namely, services for assessing the efficacy of pharmaceuticals; information, advisory and consultancy services relating to all of the aforesaid | ACTIVE | — |
| 044 | Medical services; medical analysis for the diagnosis and treatment of persons; pharmacy advice, namely, preparation of prescriptions in pharmacies and providing medical advice related to pharmaceutics; advisory services relating to health; advisory services relating to medical services; health care, namely, arranging of medical treatment; consultancy relating to health care; health advice and information services; health care; health care services; health centres being health clinic services; health clinic services; information services relating to health care; medical information retrieval services; health care, namely, medical treatment services; medical health assessment services; health care, namely, preparation of reports relating to health care matters; professional consultancy relating to health; providing health information; provision of health care services; provision of medical services; provision of medical information relating to medical practitioners; provision of medical information relating to medical specialists; services for the provision of medical care information; information, advisory and consultancy services relating to all of the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by VITARKA THERAPEUTICS LTD
- Other trademarks owned by VITARKA THERAPEUTICS LTD
- Other trademarks owned by VITARKA THERAPEUTICS LTD
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ENDOPORE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 8, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 21, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 21, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 27, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 27, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 27, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 8, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 8, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 2, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 14, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 14, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 14, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 14, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 14, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 8, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 20, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 20, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 15, 2025 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Nov 14, 2024 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Oct 14, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 14, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 14, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 10, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 10, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 10, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 10, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 10, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 10, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 2, 2024 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jul 19, 2024 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| May 8, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 17, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 17, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 31, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 30, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 26, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 22, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 21, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |